Podcast Episodes
Back to Search
The Political Shape of the Future Clinical Trial Space
The 2023 New Benchmarks on Demographic Disparities in Pivotal Trials study indicates that as Black representation increases, clinical trial enrollmen…
1 year, 11 months ago
2 Earnings Bonanza, M&A Accelerates and Alzheimer’s Data
Second-quarter earnings season continues with Big Pharma beating Wall Street expectations, the author of an encrypted email sent to BioSpace has a pr…
1 year, 11 months ago
Layoffs Persist, GLP-1s Launch for Weight Loss in China
While the biopharma industry has seen glimmers of economic optimism, there were still more than 14,000 employees laid off in the first half of 2024. …
1 year, 11 months ago
Who Is Driving The Bus - Drug Developers & Healthcare Providers or AI?
This is the third episode of Denatured's discussion on diversity, equity and inclusion (DE&I).
AI represents unlimited opportunities to increase effi…
1 year, 11 months ago
Pfizer’s Oral GLP-1 Push, Lilly Vs. Novo and PBMs Under Pressure
Pfizer stole the show late last week with the announcement that it will move forward with its oral GLP-1 analog danuglipron. While Pfizer may hope to…
1 year, 11 months ago
Lilly’s I&I Play, ADC Investment and GLP-1 Momentum Persists
After securing approval last week for Alzheimer’s drug Kisunla, Eli Lilly was back in the news Monday with the $3.2 billion acquisition of immunology…
2 years ago
FDA Approves Lilly’s Donanemab While Rejections Highlight Manufacturing Issues
The biggest news of the week was the FDA approval of Eli Lilly’s Kisunla (donanemab) on Tuesday. While not unexpected, it was one of the year’s mos…
2 years ago
DE&I: Understanding That We Don’t Understand at Molecular Level
This is the second episode of Denatured's discussion on diversity, equity and inclusion (DE&I).
Data is the essential piece for both science and tech…
2 years ago
Sarepta’s Big DMD Approval, Alnylam’s Clinical Win and ADA Highlights
The biggest news of the last week was easily the expanded approval of Sarepta’s Duchenne muscular dystrophy gene therapy, Elevidys. CBER Director Pet…
2 years ago
BioSpace at #DIA2024: Workforce Trends, Trial Design, Peter Marks & Recap
BioSpace's Lori Ellis and Chantal Dresner are bringing live updates from #DIA2024 in San Diego this week where we've been attending sessions on…
2 years ago